Iceland· IS-EU/1/23/1742/001
Columvi
A glofitamab product containing glofitamabum inn, registered in Iceland by Roche Registration GmbH*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Glofitamab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX28 (glofitamab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Glofitamab · ATC L01FX28
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Glofitamabum INN
- Manufacturer
- Roche Registration GmbH*
- Country
- Iceland (IS)
- ATC code
- L01FX28
- ATC class
- Glofitamab
- Defined daily dose
- 1.43 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Glofitamab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumColumvi 2.5 mgRoche Registration
- CzechiaCOLUMVIRoche Registration GmbH, Grenzach-Wyhlen
- FinlandColumviRoche Registration GmbH
- IrelandColumvi 2.5 mg concentrate for solution for infusionRoche Registration GmbH
- NorwayColumviRoche Registration GmbH
- PolandColumviRoche Registration GmbH
- SwedenColumvi 2,5 mg Koncentrat till infusionsvätska, lösningRoche Registration GmbH
- United StatesColumviGenentech, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Columvi
- Norway · Columvi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1e20cd3e-e3ba-499d-b7a6-ea31c0febd9f GET /v1/drugs/1e20cd3e-e3ba-499d-b7a6-ea31c0febd9f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "L01FX28",
"marketed": false,
"strength": "2,5 mg",
"ma_number": "EU/1/23/1742/001",
"substance": "Glofitamabum INN",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "45114"
}See everything about glofitamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.